CD32B | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

13 results for “CD32B”

Trials

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

14 participants · First posted Oct 14, 2016

A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

197 participants · First posted Jan 7, 2020

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

18 participants · First posted Sep 26, 2022

Drugs

CD32BxCD79B DART antibody (MacroGenics)

targeting CD320/LRP2 siRNA therapy (bioAffinity)

News

Over 220 Pipeline Therapies in Development for Non-Hodgkin's Lymphoma, Reports DelveInsight

Margetuximab Shows Promise as Alternative Therapy in HER2-Positive Advanced Breast Cancer

BioAffinity Technologies Secures Patent for Dual-Target Cancer Therapy Using siRNA Against CD320 and LRP2 Receptors

Page 1 of 2